Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
Clinical trial NCT03081923 · TERMINATED
Trial details
- NCT number
- NCT03081923
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-01
- Primary completion
- 2019-12-06
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.